Phase 0/I/II Cancer Prevention Clinical Trials Program Clinical Trials

Titlesort ascending Intervention NCT ID Sponsor Status
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer... Laboratory Biomarker Analysis, Rilimogene Galvacirepvec, Placebo Administration NCT02326805 National Cancer Institute (NCI) Active, not recruiting
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine NCT03036930 National Cancer Institute (NCI) Active, not recruiting
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-... Denosumab, Salpingo-Oophorectomy NCT03382574 National Cancer Institute (NCI) Recruiting
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Questionnaire Administration, Placebo Administration, Endoxifen Hydrochloride NCT03317405 National Cancer Institute (NCI) Active, not recruiting
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure NCT02636582 National Cancer Institute (NCI) Active, not recruiting
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine NCT03300817 National Cancer Institute (NCI) Recruiting
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Laboratory Biomarker Analysis, Metformin Hydrochloride NCT02581137 National Cancer Institute (NCI) Active, not recruiting
Iloprost in Preventing Lung Cancer in Former Smokers Iloprost, Quality-of-Life Assessment, Questionnaire Administration, Placebo Administration NCT02237183 National Cancer Institute (NCI) Active, not recruiting
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial... Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration NCT03300557 National Cancer Institute (NCI) Active, not recruiting
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous... Erlotinib Hydrochloride, Erlotinib NCT02961374 National Cancer Institute (NCI) Active, not recruiting

Pages